GlobeNewsWire
17 Aug 2026, 22:52 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
The lawsuit specifically alleges that the company failed to disclose a voluntary pause and an FDA clinical hold on the development of ARD-101. — An undisclosed FDA clinical hold is a critical regulatory failure that directly threatens the viability of a clinical-stage company's primary asset.
-0.80Aardvark Therapeutics (AARD) is facing a securities class action lawsuit alleging it made materially false and misleading statements regarding its lead drug candidate, ARD-101. — Securities litigation regarding core product efficacy and safety typically creates significant uncertainty and downward pressure on biotech stocks.
-0.60The class period for the legal action covers securities purchased between February 13, 2025, and May 14, 2026. — Defines the scope of financial liability and the group of shareholders eligible for potential recovery.
-0.20Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company is facing a securities class action lawsuit and an FDA clinical hold regarding its lead drug candidate.
Mentioned as having experienced a stock plunge due to allegedly misleading financial statements.
Mentioned as having experienced a stock plunge due to allegedly misleading financial statements.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
5h ago
